Corcept Therapeutics
$116.23Change from previous close: +1.93%Absolute change: +$2.20
At a glance
- Revenue growth
- +12.79%
- 2025 vs 2024
- Net income growth
- −29.43%
- 2025 vs 2024
- Net margin
- 13.1%
- 2024: 20.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Total revenue | 256 | 165 | 202 | 208 | 194 | — |
| Cost of revenue | 4.1 | 2.9 | 2.5 | 4.6 | 3.4 | — |
| Gross profit | 252 | 162 | 200 | 203 | 191 | — |
| Selling, general and administrative | 157 | 145 | 130 | 124 | 104 | — |
| Research and development | 53.9 | 66.3 | 64.9 | 68.8 | 60.5 | — |
| Operating income | 41.3 | -49.6 | 4.5 | 10.2 | 26.7 | — |
| EBIT | 41.3 | -49.6 | 4.5 | 10.2 | 26.7 | — |
| EBITDA | 42.2 | -49.0 | 5.0 | 10.7 | 27.1 | — |
| Pre-tax income | 45.9 | -44.7 | 9.9 | 15.2 | 31.7 | — |
| Income tax | 2.9 | -13.0 | -14.4 | -4.4 | -3.5 | — |
| Net income | 43.0 | -31.8 | 24.3 | 19.7 | 35.1 | — |
| Net income to common shareholders | 42.1 | -31.2 | 23.9 | 19.4 | 34.6 | — |
| Basic EPS | 0.40 | -0.30 | 0.23 | 0.19 | 0.33 | — |
| Diluted EPS | 0.36 | -0.30 | 0.20 | 0.16 | 0.29 | — |
| Average shares (basic) | 105 | 104 | 104 | 104 | 104 | — |
| Average shares (diluted) | 118 | 104 | 120 | 119 | 120 | — |